Equities

Scholar Rock Holding Corp

Scholar Rock Holding Corp

Actions
  • Price (USD)17.52
  • Today's Change1.19 / 7.29%
  • Shares traded149.28k
  • 1 Year change-5.35%
  • Beta--
Data delayed at least 15 minutes, as of Feb 25 2020 19:38 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.

  • Revenue in USD (TTM)12.92m
  • Net income in USD-54.39m
  • Incorporated2017
  • Employees69.00
  • Location
    Scholar Rock Holding Corp620 Memorial Dr Fl 2CAMBRIDGE 02139-4815United StatesUSA
  • Phone+1 (857) 259-3860
  • Fax+1 (302) 655-5049
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mirum Pharmaceuticals Inc-100.00bn-100.00bn468.45m29.00--2.85----------6.48----------------------------0.00--------------
Atreca Inc0.00-59.36m471.15m102.00--2.92-----2.19-2.190.007.33------0.00--------------------0.0005-------37.83------
BioDelivery Sciences International, Inc.97.78m-21.62m472.04m164.00--6.94--4.83-0.282-0.2821.180.75620.67642.274.25596,225.60-14.95-46.36-19.77-67.3181.2472.96-22.11-85.142.02-0.07070.4629---10.2437.41-977.33--7.81--
CytoDyn Inc0.00-58.49m473.83m10.00---------0.1722-0.17220.00-0.03420.00----0.00-305.38-396.98---------------7.28---------12.04--18.69--
Calithera Biosciences Inc0.00-87.63m477.52m79.00--3.35-----2.08-2.080.002.240.00----0.00-59.61-33.84-66.17-38.25-------362.62----0.00---14.26---96.32--5.47--
Xenon Pharmaceuticals Inc3.50m-37.26m479.50m89.00--5.95--137.00-1.45-1.450.13642.880.0305--17.9939,325.84-33.81-25.73-36.37-28.64100.00---1,107.91-197.42----0.1712---100.00---2.97--26.58--
Morphic Holding Inc20.67m-28.84m480.12m65.00--2.97--23.23-0.9704-0.97040.6965.31------558,594.60-------------139.54------0.00-------40.85------
Scholar Rock Holding Corp12.92m-54.39m484.65m69.00--3.98--37.51-2.41-2.410.5364.100.0868----198,753.80-36.56---41.96-------421.03------0.00-------97.34------
Prothena Corporation PLC814.00k-77.68m486.34m59.00--1.78--597.47-1.95-1.950.02046.840.0018-------16.92-28.50-17.55-30.30-----9,542.63-1,964.57---------14.76-56.2650.09------
Puma Biotechnology Inc272.24m-75.60m488.96m272.00------1.80-1.95-1.957.02------------------86.49---27.77-180.85---3.20----8.49--33.44------
Beyondspring Inc0.00-38.13m490.29m52.00--22.31-----1.62-1.620.000.7886------0.00-------------------159.570.0591------40.21------
Neoleukin Therapeutics Inc0.00-66.23m491.09m8.00--4.25-----2.56-2.560.002.380.00----0.00-84.04-35.82-91.80-38.65-------667.83----0.0032------39.82--34.82--
Viking Therapeutics Inc0.00-23.57m493.56m15.00--1.74-----0.3282-0.32820.003.920.00----0.00-7.90-49.74-8.04-62.44------------0.00-------7.22------
Magenta Therapeutics Inc0.00-70.21m495.56m72.00--3.06-----1.97-1.970.004.150.00----0.00-40.12---42.75--------------0.00-------62.23------
89bio Inc0.00-42.78m499.85m17.00---------3.55-3.550.00-0.3502------0.00------------------------------------
Merus NV32.41m-29.38m501.31m98.00--5.32--15.47-1.26-1.261.393.260.1441--12.12330,719.90-13.06-41.80-15.62-49.24-----90.64-299.35----0.0208--43.50123.9762.53--79.62--
Data as of Feb 25 2020. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD

Institutional shareholders

56.50%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 20194.45m15.00%
Redmile Group LLCas of 31 Dec 20192.94m9.91%
Bellevue Asset Management AGas of 31 Dec 20192.63m8.88%
Invus Public Equities Advisors LLCas of 31 Dec 20192.55m8.58%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20191.26m4.24%
BlackRock Fund Advisorsas of 31 Dec 20191.17m3.95%
The Vanguard Group, Inc.as of 31 Dec 2019905.65k3.05%
SSgA Funds Management, Inc.as of 31 Dec 2019354.48k1.19%
Norges Bank Investment Managementas of 31 Dec 2018255.00k0.86%
Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2019247.68k0.84%
More ▼
Data from 31 Dec 2018 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.